ACLX Arcellx, Inc.

Q3 2025 10-Q

Filed: Nov 5, 2025Period ending Sep 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Arcellx, Inc. (ACLX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No revenue or profitability data disclosed in this section
• No segment or product line performance details provided

+2 more insights

Risk Factors

• New FDA clinical hold risk on anito-cel triggered by previous partial hold requires costly and time-consuming mitigation measures
• Net loss $170.8M for nine months ended Sept 30, 2025 vs $60.3M prior year, reflecting increased R&D and operational costs

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$5M

▼ -81.0% YoY▼ -34.5% QoQ

Net Income

-$56M

▼ -115.6% YoY▼ -5.7% QoQ

Operating Margin

-1248.3%

▼ -111911bp YoY▼ -47084bp QoQ

Net Margin

-1127.1%

▼ -102774bp YoY▼ -42853bp QoQ

ROE

-12.7%

Total Assets

$656M

EPS (Diluted)

$-1.00

▼ -108.3% YoY▼ -7.5% QoQ

Operating Cash Flow

-$49M

▼ -260.2% YoY▼ -23.9% QoQ

Source: XBRL data from Arcellx, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Arcellx, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.